Advocacy for Regulatory Flexibility in Rare Disease Therapies
Explore the urgent call for regulatory flexibility in rare disease therapies, as industry leaders seek solutions to expedite drug approvals amid strict FDA guidelines.
High-Cost Gene Therapies Challenge U.S. Insurance and Employer Coverage
Explore how high-cost gene therapies like Zolgensma are affecting U.S. employer-sponsored insurance and healthcare coverage amid rising costs and manufacturing challenges.